The Eurasian Journal of Medicine
Case Report

Myasthenia Gravis Attack after Oral Risperidone Treatment: A Case Report

Eurasian J Med 2018; 50: 128-129
DOI: 10.5152/eurasianjmed.2018.17296
Read: 1815 Downloads: 768 Published: 03 September 2019



Myasthenia gravis (MG) is an autoimmune disease, which can be triggered by anticholinergic agents. The 6-year-old female patient was admitted to the outpatient clinic. She was had been previously diagnosed with comorbid attention deficit hyperactivity disorder and conduct disorder and was receiving short-acting methylphenidate and risperidone, as recommended by a child psychiatrist. However, after using the drugs, she stated that she was overly tired during the day and that her eyelids drooped. Hence, the current treatment was stopped. She was hospitalized with a prediagnosis of ocular type MG and pyridostigmine (90 mg/day) treatment was started. The patient recovered and subsequently the treatment was stopped. Since psychiatric symptoms of the patient resurfaced, long-acting methylphenidate treatment was initiated. During this treatment, the symptoms of MG did not return. The Naranjo’s scale of adverse drug reaction probability was completed. Consequently, there may be an association between risperidone and MG.



Cite this article as: Ogutlu H, Karayagmurlu A, Esin IS,  Dursun OB. Myasthenia Gravis Attack after Oral Risperidone Treatment: A Case Report. Eurasian J Med 2018; 50: 128-9.

EISSN 1308-8742